Immunosuppressants: Cellular and molecular mechanisms of action

American Journal of Kidney Diseases

Volumn 28, Issue 2, 1996, Pages 159-172

  Suthanthiran, Manikkam ^a   Morris, Randall E ^a   Strom, Terry B ^a  

^a Box 3 ^*

Author keywords

antiallograft response; cytokines; Immunosuppressants; monoclonal antibodies

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEFLUNOMIDE; LYMPHOCYTE ANTIBODY; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS;

DRUG EFFECT; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; GROWTH INHIBITION; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; PROTEIN SYNTHESIS INHIBITION; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION;

EID: 0029797781     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(96)90297-8     Document Type: Review

References (109)

1. Unanue ER, Cerottoni J-C: Antigen presentation. FASEB J 3:2496-2502, 1989
2. Germain RN: MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell 76:287-299, 1994
3. Suthanthiran M, Strom TB: Renal transplantation. N Engl J Med 331:365-376, 1994
4. Weiss A, Littman DR: Signal transduction by lymphocyte antigen receptors. Cell 76:263-264, 1994
5. Clevers H, Alarcon B, Wileman T, Terhorst C: The T-cell receptor/CD3 complex: A dynamic protein ensemble. Annu Rev Immunol 6:629-662, 1988
6. Shoskes DA, Wood KJ: Indirect presentation of MHC antigens in transplantation. Immunol Today 15:32-38, 1994
7. Miceli MC, Parnes JR: The role of CD4 and CD8 in T-cell activation. Semin Immunol 3:133-141, 1991
8. Suthanthiran M: A novel model for antigen-dependent activation of normal human T-cells. Transmembrane signaling by crosslinkage of the CD3/T cell receptor-α/β complex with the cluster determinant 2 antigen. J Exp Med 171:1965-1979, 1990
9. Brown MH, Cantrell DA, Brattsand G, Crumpton MJ, Gullberg M: The CD2 antigen associates with the T-cell antigen receptor/CD3/antigen complex on the surface of human T lymphocytes. Nature 339:551-553, 1989
10. Beyers AD, Spruyt LL, Williams AF: Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. Proc Natl Acad Sci U S A 89:2945-2949, 1992
11. Klausner RD, Samelson LE: T-cell antigen receptor activation pathways: The tyrosine kinase connection. Cell 64:875-878, 1991
12. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607-614, 1992
13. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA: FK 506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 357:692-694, 1992
14. Clipstone NA, Crabtree GR: Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357:695-697, 1992
15. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815, 1991
16. Fruman DA, Klee CB, Bierer BE, Burakoff SJ: Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A 89:3686-3690, 1992
17. Schwartz RH: T-cell anergy. Sci Am 269:62-71, 1993
18. Suthanthiran M: Signaling features of T-cells: Implications for the regulation of the anti-allograft response. Kidney Int 44:S3-S11, 1993
19. Dustin ML, Springer TA: T-cell receptor crosslinking transiently stimulates adhesiveness through LFA-1. Nature 341:619-624, 1989
20. June CH, Ledbetter JA, Linsley PS, Thompson CB: Role of the CD28 receptor in T-cell activation. Immunol Today 11:211-216, 1990
21. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B-cell activation antigen B7. J Exp Med 174:561-569, 1991
22. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH: CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A 86:1333-1337, 1989
23. Allison JP, Krummel MF: The yin and yang of T cell costimulation. Science 270:932-933, 1995
24. Isobe M, Yagita H, Okumura K, Ihara A: Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 255:1125-1127, 1992
25. Lenschow J, Zeng Y, Thistlethwaite R, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4Ig. Science 257:789-792, 1992
26. Williams JM, DeLoria D, Hansen JA, Dinarello CA, Loertscher R, Shapiro HM, Strom TB: The events of primary T-cell activation can be staged by use of sepharose-bound anti-T3 [64.1] monoclonal antibody and purified interleukin-1. J Immunol 135:2249-2255, 1985
27. Bretcher P, Cohen M: A theory of self-nonself discrimination: Paralysis and induction involve the recognition of one and two determinants on an antigen, respectively. Science 169:1042-1049, 1970
28. Clark EA, Ledbetter JA: How B- and T-cells talk to each other. Nature 367:425-428, 1994
29. Schreiber SC: Immunophilin-sensitive protein phosphatase activation in cell signaling pathways. Cell 70:365-368, 1992
30. Roberts AB, Sporn MB: Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 8:1-9, 1993
31. Li B, Sehajpal PK, Khanna A, Vlassara H, Cerami A, Stenzel KH, Suthanthiran M: Differential regulation of transforming growth factor beta and interleukin-2 genes in human T-cells: Demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med 174:1259-1262, 1991
32. Khanna A, Li B, Stenzel KH, Suthanthiran M: Regulation of new DNA synthesis in mammalian cells by cyclosporine. Demonstration of a transforming growth factor β-dependent mechanism of inhibition of cell growth. Transplantation 57:577-582, 1994
33. Knudsen PJ, Dinarello CA, StromTB: Glucocorticoids inhibit transcription and post-transcriptional expression of interleukin-1. J Immunol 139:4129-4134, 1987
34. Zanker B, Walz G, Wieder KJ, Strom TB: Evidence that glucocorticosteroids block expression of the human interleukin-6 gene by accessory cells. Transplantation 49:183-185, 1990
35. Arya SK, Wong-Staal F, Gallo RC: Dexamethasone mediated inhibition of T-cell growth factor and gamma interferon messenger RNA. J Immunol 133:273-276, 1984
36. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB: Abrogation of glucocorticosteroid-mediated inhibition of T-cell proliferation by the synergistic action of IL-1, IL-6, and IFN. J Immunol 146:3523-3527, 1991
37. Vacca A, Felli MP, Farina AR, Martinotti S, Maroder M, Screpanti I, Meco D, Petrangeli E, Frati L, Gulino A: Glucocorticoid receptor-mediated suppression of the interleukin-2 gene expression through impairment of the cooperativity between nuclear factor of activated T-cells and AP-1 enhancer elements. J Exp Med 175:637-646, 1992
38. Yang-Yee HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, Karin M: Transcriptional interference between cp-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62:1205-1215, 1990
39. Palvogianni F, Raptis A, Ahuja SS, Najjar SM, Boumpas DT: Negative transcriptional regulation of human interleukin-2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest 91:1481-1487, 1993
40. Scheinman RI, Cogswell PG, Lofquist AK, Baldwin AS Jr: Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270:283-286, 1995
41. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NFκB activity through induction of IκB synthesis. Science 270:286-290, 1995
42. Elion GB: Biochemistry and pharmacology of purine analogues. Fed Proc 26:898-904, 1967
43. Morris RE: Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 6:39-87, 1992
44. Sehgal SN, Camardo JS, Scarola JA, Maida BT: Rapamycin (sirolimus, rapamune). Curr Opin Nephrol Hypertens 4:482-487, 1995
45. Chung J, Kuo CJ, Crabtree GR, Blenis J: Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 69:1227-1236, 1992
46. Heitman J, Movva NR, Hall MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905-909, 1991
47. Sabatini DM, Erdjument Bromage H, Lui M, Tempst P, Snyder SH: Raft-1: A mammalian protein that binds to FKBP 12 in a rapamycin dependent fashion and is homologous to yeast TORS. Cell 78:35-43, 1994
48. Lai JH, Tan H: CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin. J Biol Chem 269:30077-30080, 1994
49. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R, Billingham ME, Morris RE: Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 59:655-661, 1995
50. Morris RE, Wang J: Comparison of the immunosuppressive effects of mycophenolic acid and the morpholinethal ester of mycophenolic acid (RS-61443) in recipients of heart grafts. Transplant Proc 23:493-506, 1991
51. Allison AC, Eugui EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 136:5-19, 1993
52. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325, 1995
53. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60:225-232, 1995
54. Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS: Guanine ribonucleotide depletion inhibits T-cell activation: Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest 87:940-948, 1991
55. Kokado Y, Ishibahi M, Jiang H: Low dose ciclosporin, mizoribine and prednisone in renal transplantation: A new triple drug therapy. Clin Transplant 4:191-197, 1990
56. Takeuchi T, Iinuma H, Kunimoto S, Masuda T, Ishizuka M, Takeuchi M, Hamada M, Naganawa H, Kondo S, Umezawa H: A new antitumor antibiotic, spergualin: isolation and antitumor activity. J Antibiot (Tokyo) 34:1619-1621, 1981
57. Umeda Y, Moriguchi M, Kuroda H, Nakamura T, Iinuma H, Takeuchi T, Umezawa H: Synthesis and antitumor activity of spergualin analogues. I. Chemical modification of 7-guanidino-3-hydroxyacyl moiety. J Antibiot (Tokyo) 38:886-898, 1985
58. Nadler SG, Tepper MA, Schacter B, Mazzucco CE: Interaction of the immuno-suppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 258:484-486, 1992
59. Makowka L, Sher LS, Cramer DV: The development of brequinar as an immunosuppressive drug for transplantation. Immunol Rev 136:51-70, 1993
60. Fox RI, Morris RE: Inhibitors of de novo nucleotide synthesis in the treatment of rheumatoid arthritis, in Strand V (ed): Emerging Therapies for Autoimmune Diseases. New York, NY, Marcel Dekker, 1996 (in press)
61. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, Dimitrijevic M, Zivkovic M, Campion G, Musikic P, Low-Friedrich I, Oed C, Seifert H, Strand V: Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 38:1595-1603, 1995
62. Cao WW, Kao PN, Chao AC, Gardener P, Ng J, Morris RE: Mechanism of the antiproliferative action of leflunomide: A77 1726, the active metabolite of leflunomide, does not block T cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. J Heart Lung Transplant 14:1016-1030, 1995
63. Yuh D, Gandy KL, Morris RE, Hoyt G, Guiterrez J, Reitz B, Robbins R: Leflunomide prolongs pulmonary allograft and xenograft survival. J Heart Lung Transplant 14:1136-1144, 1995
64. Lin Y, Sobis H, Vandeputte M, Waer M: Mechanism of leflunomide-induced prevention of xenoantibody formation and xenograft rejection in the hamster to rat heart transplantation model. Transplant Proc 27:305-306, 1995
65. Xiao F, Chong AS, Foster P, Sankary H, McChesney L, Koukoulis G, Yang J, Frieders D, Williams JW: Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 58:828-834, 1994
66. Kurtz ES, Bailey SC, Arshad F, Lee AA, Przekop PA: Leflunomide: An active antiinflammatory and antiproliferative agent in models of dermatologic disease. Inflamm Res (Switzerland) 44:S187-S188, 1995 (suppl 2)
67. Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT: Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res (Switzerland) 44:317-322, 1995
68. Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, Woodward K, Bruneau J-M, Hambleton P, Moss D, Thomson TA, Spinella-Jacgle S, Morand P, Courtin O, Sautés C, Westwood R, Hercend T, Kuo EA, Ruuth E: Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 270:22467-22472, 1995
69. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu Y-Z, Caulfield JP, Young JM, Nakano G, Ransom JT: The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 275:1043-1049, 1995
70. Greene S, Watanabe K, Braatz-Trulson J, Lou L: Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 50:861-867, 1995
71. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS-F: Inhibition of protein tyrosine phosphorylation in T cells by a novel immnosuppressive agent, leflunomide. J Biol Chem 270:12398-12403, 1995
72. Nair RV, Cao W, Morris RE: Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Immunol Lett 47:171-174, 1995
73. Morris RE, Iluang XF, Shorthouse R, Reichenspurner H, Adams B, Berry G: Studies in experimental models of chronic rejection: Use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogues) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 27:2068-2069, 1995
74. Helderman JH: Review and preview of anti-T-cell antibodies. Transplant Proc 27:8-9, 1995
75. Norman DJ: Antilymphocyte antibodies in the treatment of allograft rejection: Targets, mechanisms of action, monitoring, and efficacy. Semin Nephrol 12:315-324, 1992
76. Cecka JM, Cho YW, Terasaki PI: Analysis of the UNOS scientific renal transplant registry at three years - Early events affecting transplant success. Transplantation 53:59-64, 1992
77. Filo RS, Smith EJ, Leapman SB: Therapy of acute cadaveric renal allograft rejection with adjunctive antithymocyte globulin. Transplantation 30:445-449, 1980
78. Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337-342, 1985
79. Suthanthiran M, Fotino M, Riggio RR, Cheigh JS, Stenzel KH: OKT3-associated adverse reactions: Mechanistic basis and therapeutic options. Am J Kidney Dis 14:39-44, 1989
80. Vincenti FG, Vasconcelos M, Birnbaum HL, Tomlanovich SJ, Amend WJC Jr, Melzer JS, Snyder JP: Pentoxifylline reduces the first-dose reactions following OKT3. Transplant Proc 25:57-59, 1993
81. First MR, Schroeder TJ, Hariharan S, Weiskittel P: Reduction of the initial febrile response to OKT3 with indomethacin. Transplant Proc 25:52-54, 1993
82. Chatenoud L: OKT3-induced cytokine-release syndrome: Preventive effect of anti-tumor necrosis factor monoclonal antibody. Transplant Proc 25:47-51, 1993
83. Waid TH, Lucas BA, Thompson JS, Brown SA, Munch L, Prebeck RJ, Jezek D: Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 53:80-86, 1992
84. Yoshimura N, Takahashi K, Ishibashi M: Treatment of acute cellular rejection with BMA031 in renal transplant recipients - A multi centered trial in Japan. Proceedings of the meeting of the American Society of Transplant Surgeons, Chicago, IL, May 1992, p 63 (abstr)
85. Soulillou J-P, Cantarovich D, Le Mauff B, Gival M, Robillard N, Hourmant M, Him M, Jacques Y: Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 322:1175-1182, 1990
86. Kirkman RL, Shapiro ME, Carpenter CB, McKay DR, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB: A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 51:107-113, 1991
87. Goodman ER, Hardy MA: Transplantation 1992: The year in review, in Terasaki PI, Cecka JM (eds): Clinical Transplants 1992. Los Angeles, CA, UCLA Tissue Typing Laboratory, 1993, pp 285-297
88. Ettinger RM, Yadin O: The potential role of therapeutic antibodies in the regulation of rejection. Transplant Proc 27:13-17, 1995
89. Qin L, Chavin KD, Lin J, Yagita H, Bromberg JS: Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. J Exp Med 179:341-346, 1994
90. Kapur S, Khanna A, Sharma VK, Li B, Suthanthiran M: CD2 antigen targeting reduces intragraft expression of mRNA encoding granzyme B and IL-10 and induces tolerance. Transplantation 62:1996 (in press)
91. Turka LA, Linsley H, Lin W, Brady W, Leiden JM, Wei RQ, Gibson ML, Zheng XG, Myrdal S, Gordon D: T cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A 89:11102-11105, 1992
92. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA: A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 86:10029-10033, 1989
93. Meyers BD: Cyclosporine nephrotoxicity. Kidney Int 30:964-974, 1986
94. Weir MR: Clinical benefits of calcium antagonists in renal transplant recipients, in Epstein M (ed): Calcium Antagonists in Clinical Medicine. Philadelphia, PA, Hanley and Belfus, 1992, pp 391-412
95. Schrier RW, Arnold PE, Van Putten VJ, Burke TJ: Cellular calcium in ischemic acute renal failure: Role of calcium entry blockers. Kidney Int 32:313-322, 1987
96. Neumayer H-H, Kunzendorf U, Schreiber M: Protective effects of calcium antagonists in human renal transplantation. Kidney Int 41:S87-S93, 1992
97. Kunzendorf U, Walz G, Brockmoeller J, Neumayer HH, Jochinsen F, Roots I, Offermann G, Strom TB: Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation 52:280-284, 1991
98. Dawidson I, Rooth P, Lu C, Sagalowsky A, Diller K, Palmer B, Peters P, Risser R, Sandor Z, Seney F: Verapamil improves the outcome after cadaver renal transplantation. J Am Soc Nephrol 2:983-990, 1991
99. Suthanthiran M, Haschemeyer RH, Riggio RR, Adubor C, Friedman GS, Cheigh JS, Wang JC, Fotino M, Stubenbord WT, Saal SD, Stenzel KH, Rubin AL: Excellent outcome with a calcium channel blocker supplemented immunosuppressive regimen in cadaveric renal transplantation: A potential strategy to avoid antibody induction protocols. Transplantation 55:1008-1013, 1993
100. Weir MR, Suthanthiran M: Supplementation of immunosuppressive regimens with calcium channel blockers. Rationale and clinical efficacy. Clin Immunother 2:458-467, 1994
101. Pirsch JD, D'Alessandro AM, Roecker EB, Knechtle SJ, Reed A, Solinger HW, Kalayoglu M, Belzer FO: A controlled, double-blind, randomized trial of verapamil and cyclosporine in cadaver renal transplant patients. Am J Kidney Dis 21:189-195, 1993
102. Kelley VE, Kirkman RL, Bastos M, Barrett LV, Strom TB: Enhancement of immunosuppression by substitution of fish oil for olive oil as a vehicle for cyclosporine. Transplantation 48:98-102, 1989
103. Rogers TS, Elzinga L, Bennett WM, Kelley VE: Selective enhancement of thromboxane in macrophages and kidneys in cyclosporine-induced nephrotoxicity. Dietary protection by fish oil. Transplantation 45:153-156, 1988
104. Van Der Heide JJH, Bilo HJG, Donker JM, Wilmink JM, Tegzess AM: Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 329:769-773, 1993
105. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A: Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 333:628-633, 1995
106. First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW: Cyclosporine-ketoconazole interaction: Long-term follow up and preliminary results of a randomized trial. Transplantation 55:1000-1004, 1993
107. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627, 1995
108. Strom TB, Suthanthiran M: Mechanisms of graft rejection, in Sayegh MH, Turka LA (eds): ASTP Lectures in Transplantation. Philadelphia, PA, CoMed Communications, 1996
109. Schreier MH, Zenke G, Borel F, Baumann G: The continuing search for new immunomodulators. Transplant Proc 25:502-507, 1993